Gilead Sciences (GILD) Short term Debt (2009 - 2026)

Gilead Sciences (GILD) has reported Short term Debt for 18 consecutive years, with $1.3 billion the latest figure, recorded in Q1 2026.

• Short term Debt for Q1 2026 came in at $1.3 billion, down 53.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (down 53.21% YoY), and the FY2025 annual result was $2.8 billion, up 54.66% from the prior year.
• Short term Debt was $1.3 billion for Q1 2026 at Gilead Sciences, down from $2.8 billion in the prior quarter.
• Over five years, Short term Debt peaked at $4.0 billion in Q2 2023 and troughed at $1.0 billion in Q2 2022.
• Average Short term Debt over 5 years is $2.2 billion, with a median of $2.3 billion recorded in 2022.
• Year-over-year, Short term Debt jumped 295.4% in 2023 and plunged 55.16% in 2024.
• Over 5 years, Short term Debt stood at $2.3 billion in 2022, then dropped by 20.9% to $1.8 billion in 2023, then grew by 0.95% to $1.8 billion in 2024, then jumped by 54.66% to $2.8 billion in 2025, then plunged by 53.22% to $1.3 billion in 2026.
• Per Business Quant data, the three most recent Short term Debt figures were $1.3 billion in Q1 2026, $2.8 billion in Q4 2025, and $2.8 billion in Q3 2025.